The Important Role of Inflammatory Biomarkers Pre and Post Bare-Metal and Drug-Eluting Stent Implantation

Canadian Journal of Cardiology

Volumn 28, Issue 6, 2012, Pages 700-705

  Khouzam, Rami N ^a   Shaheen, Mazen ^a   Aziz, Ramy K ^b   Ibebuogu, Uzoma N ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GELATINASE A; GELATINASE B; GLYCOSYLPHOSPHATIDYLINOSITOL; INTERLEUKIN 6; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREGNANCY ASSOCIATED PLASMA PROTEIN A; STEROID; TOLL LIKE RECEPTOR 2;

ALLERGY; BARE METAL STENT; DRUG EFFECT; DRUG ELUTING STENT; GENETIC POLYMORPHISM; HUMAN; IN-STENT RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; STENT THROMBOSIS; STEROID THERAPY; VASCULAR SMOOTH MUSCLE;

BIOLOGICAL MARKERS; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; INFLAMMATION; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROGNOSIS;

EID: 84869089627     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.05.012     Document Type: Review

References (42)

1. Niccoli G., Montone R., Ferrante G., Crea F. The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol 2010, 56:1783-1793.
2. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007, 370:937-948.
3. Virmani R., Liistro F., Stankovic G., et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 2002, 106:2649-2651.
4. Wessely R., Kastrati A., Schömig A. Late restenosis in patients receiving a polymer coated sirolimus-eluting stent. Ann Intern Med 2005, 143:392-394.
5. Park D.W., Yun S.C., Lee J.Y., et al. C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation. Circulation 2009, 120:1987-1995.
6. Buffon A., Liuzzo G., Biasucci L.M., et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999, 34:1512-1521.
7. Montone R.A., Ferrante G., Bacà M., Niccoli G. Predictive value of C-reactive protein after drug-eluting stent implantation. Future Cardiol 2010, 6:167-179.
8. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007, 370:937-948.
9. Farb A., Sangiorgi G., Carter A.J., et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999, 99:44-52.
10. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448-454.
11. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
12. Virmani R., Guagliumi G., Farb A., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 2004, 109:701-705.
13. Cook S., Ladich E., Nakazawa G., et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 2009, 120:391-399.
14. Jones G.T., Kay I.P., Chu J.W., et al. Elevated plasma active matrix metalloproteinase-9 level is associated with coronary artery in-stent restenosis. Arterioscler Thromb Vasc Biol 2006, 26:e121-e125.
15. Otsuka M., Hayashi Y., Ueda H., Imazu M., Kohno N. Predictive value of pre-procedural fibrinogen concerning coronary stenting. Atherosclerosis 2002, 164:371-378.
16. Christ G., Nikfardjam M., Huber-Beckmann R., et al. Predictive value of plasma plasminogen activator inhibitor-1 for coronary restenosis: dependence on stent implantation and antithrombotic medication. J Thromb Haemost 2005, 3:233-239.
17. Turker S., Guneri S., Akdeniz B., et al. Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease. Am J Cardiol 2006, 97:198-202.
18. Van Tiel C.M., Bonta P.I., Rittersma S.Z., et al. p27kip1-838C_A single nucleotide polymorphism is associated with restenosis risk after coronary stenting and modulates p27kip1 promoter activity. Circulation 2009, 120:669-676.
19. Monraats P.S., Pires N.M., Agema W.R., et al. Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. Circulation 2005, 112:2417-2425.
20. Toutouzas K., Colombo A., Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J 2004, 25:1679-1687.
21. Montone R.A., Ferrante G., Baca M., Niccoli G. Predictive value of C-reactive protein after drug-eluting stent implantation. Future Cardiol 2010, 6:167-179.
22. Chung I.M., Gold H.K., Schwartz S.M., Ikari Y., Reidy M.A., Wight T.N. Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. J Am Coll Cardiol 2002, 40:2072-2081.
23. De Labriolle A., Bonello L., Lemesle G., et al. Clinical presentation and outcome of patients hospitalized for symptomatic in-stent restenosis treated by percutaneous coronary intervention: comparison between drug-eluting stents and bare-metal stents. Arch Cardiovasc Dis 2009, 102:209-217.
24. Gaspardone A., Crea F., Versaci F., et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol 1998, 82:515-518.
25. Segev A., Kassam S., Buller C.E., et al. Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting. Eur Heart J 2004, 25:1029-1035.
26. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006, 48:193-202.
27. Alfonso F., Perez-Vizcayno M.J., Ruiz M., et al. Coronary aneurysms after drug-eluting stent implantation: clinical, angiographic, and intravascular ultrasound findings. J Am Coll Cardiol 2009, 53:2053-2060.
28. Le M.Q., Narins C.R. Mycotic pseudoaneurysm of the left circumflex coronary artery: a fatal complication following drug-eluting stent implantation. Catheter Cardiovasc Interv 2007, 69:508-512.
29. Park D.W., Lee C.W., Yun S.C., et al. Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation. Heart 2007, 93:1087-1092.
30. Gaspardone A., Versaci F., Tomai F., et al. C-Reactive protein, clinical outcome, and restenosis rates after implantation of different drug-eluting stents. Am J Cardiol 2006, 97:1311-1316.
31. Pichler W.J. Delayed drug hypersensitivity reactions. Ann Intern Med 2003, 139:683-693.
32. Rittersma S.Z., Meuwissen M., van der Loos C.M., et al. Eosinophilic infiltration in restenotic tissue following coronary stent implantation. Atherosclerosis 2006, 184:157-162.
33. Jaffe R., Strauss B.H. Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives. J Am Coll Cardiol 2007, 50:119-127.
34. Hoshida S., Nishino M., Takeda T., Tanouchi J., Yamada Y., Hori M. A persistent increase in C-reactive protein is a risk factor for restenosis in patients with stable angina who are not receiving statins. Atherosclerosis 2004, 173:285-290.
35. Pasceri V., Patti G., Nusca A., Pristipino C., Richichi G., Di Sciascio G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) study. Circulation 2004, 110:674-678.
36. Versaci F., Gaspardone A., Tomai F., et al. Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol 2002, 40:1935-1942.
37. Whatling C., McPheat W., Herslof M. The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field. Expert Opin Investig Drugs 2007, 16:1879-1893.
38. Waksman R. Promise and challenges of bioabsorbable stents. Catheter Cardiovasc Interv 2007, 70:407-414.
39. Steffel J., Eberli F.R., Lüscher T.F., Tanner F.C. Drug-eluting stents - what should be improved?. Ann Med 2008, 40:242-252.
40. Byrne R.A., Iijima R., Mehilli J., et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv 2009, 2:291-299.
41. Chen J.P., Hou D., Pendyala L., et al. Drug-eluting stent thrombosis: the Kounis hypersensitivity-associated acute coronary syndrome revisited. JACC Cardiovasc Interv 2009, 2:583-593.
42. Kounis N.G., Kounis G.N., Kouni S.N., et al. Allergic reactions following implantation of drug-eluting stents: a manifestation of Kounis syndrome?. J Am Coll Cardiol 2006, 48:592-593.